Log in
Enquire now
‌

Abterra Biosciences, Inc. SBIR Phase I Award, April 2020

A SBIR Phase I contract was awarded to Digital Proteomics in April, 2020 for $217,313.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health.

OverviewStructured DataIssuesContributors

Contents

sbir.gov/node/1912607
Is a
SBIR/STTR Awards
SBIR/STTR Awards

SBIR/STTR Award attributes

SBIR/STTR Award Recipient
Digital Proteomics
Digital Proteomics
0
Government Agency
0
Government Branch
National Institutes of Health
National Institutes of Health
0
Award Type
SBIR0
Contract Number (US Government)
1R43GM137688-010
Award Phase
Phase I0
Award Amount (USD)
217,3130
Date Awarded
April 1, 2020
0
End Date
September 30, 2021
0
Abstract

Project SummaryAntibodies are vital molecules produced by the adaptive immune system, and are a critical component in identifying foreign agents for removal within an organism. Produced by B cells, antibodies have an enormously diverse set of possible compositions, created by somatic recombination and hypermutation processes that are specific to these types of immune cells. Due to their incredible diversity, studying them for the purpose of antibody discovery or disease characterization, becomes a difficult task.Recently, next-generation sequencing (NGS) technologies have been successfully applied to study the diverse repertoire of antibodies produced by B cells. This technology has proven incredible for understanding this component of the immune response in a new level of detail. Unfortunately, NGS produced strings contain errors as part of the process. These errors can be confused as true sequence diversity, and can confound downstream analysis and interpretation. Furthermore, structuring such deep sequenced antibody repertoire data for answering questions about the immune response is non-trivial and compute resource intensive; problems that not many labs are well suited to address.Our proposal seeks to break down barriers for entry of these repertoire sequencing assays by providing innovative informatics approaches to error correction and analysis, delivering results in an interactive cloud platform. Our service will be the first to offer non-human/mouse species support, as well as support for transgenic animals, critical for many drug discovery companies.Project Narrative Antibody molecules are created by the immune system used to target cancer, pathogens, and other foreign agents. Understanding the population of antibody molecules within a single individual requires sequencing their nucleotide composition. This process can generate millions of unique strings of nucleotides, of which a small proportion are erroneous. Tools for correcting, analyzing, and visualizing such intricate datasets require improved informatics approaches to make decisions in research and development of vaccines and drugs.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like Abterra Biosciences, Inc. SBIR Phase I Award, April 2020

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.